Wednesday, July 24, 2019 Daily Archives

Standardized Plasmids for Viral Vector Production

In this Tuesday, 4 June 2019, presentation at the BPI Theater at BIO, James Brown, vice president of corporate development at Aldevron, chronicled the development of his firm’s off-the-shelf plasmid products. Offering examples of the key partnerships that Aldevron has forged in the industry, including its collaboration with Asklepios BioPharmaceutical in producing the PLDX80 proprietary helper plasmid, Brown explained how Aldevron’s standardized plasmids can help companies to produce the viral vectors needed for novel gene therapies.

BIA Separations providing chromatography columns for AveXis

BIA Separations’ prepacked chromatography columns “contribute to a robust manufacturing process” for the recently approved gene therapy Zolgensma, says AveXis. In May, the US Food and Drug Administration (FDA) approved Zolgensma (onasemnogene abeparvovec), a gene therapy designed to halt progressive spinal muscular atrophy (SMA). Novartis subsidiary AveXis developed and commercialized the $2.1 million one-off treatment, but – as the saying goes – it takes a village to raise a child. Zolgensma relies on Regenxbio’s adeno-associated virus (AAV) vector technology, and…